

1 **Acceptability and sustainability of a point-of-care HPV ‘self-collect, screen-and-treat’ for**
2 **cervical cancer prevention in Papua New Guinea: A qualitative exploration of key informants’**
3 **perspectives**

4
5
6 Authors: Hawa Camara¹ *, Somu Nosi², Gloria Munnall^{2 3}, Steven G. Badman¹, John Bolgna³,
7 Joseph Kuk⁴, Glen Mola⁵, Rebecca Guy¹, Andrew J. Vallely^{1 2}, and Angela Kelly-Hanku^{1 2}

8
9 **Affiliation:**

10 ¹Kirby Institute for Infection and Immunity in Society, UNSW Sydney, Wallace Wurth Building, NSW 2052 Australia

11 ²Papua New Guinea Institute of Medical Research, Homate Street, PO Box 60, Goroka, Eastern Highlands Province

12 ³Modilon General Hospital, Department of Obstetrics & Gynaecology, PO Box 1200, Madang, Papua New Guinea

13 ⁴Mt Hagen Provincial Hospital, PO Box 36, Mt Hagen, WHP 281, Papua New Guinea

14 ⁵School of Medicine and Health Sciences, University of Papua New Guinea, PO Box 5623 Boroko, NCD, PNG

15
16 *Corresponding author

17
18 **Abstract:**

19
20 **Introduction:** Innovative technologies over the past decade have emerged to increase uptake in
21 cervical cancer early detection and treatment that could significantly improve screening and
22 precancerous treatment. The changing landscape in cervical cancer screening algorithms and
23 technologies calls for critical inquiries into their implementation in all settings, but especially in
24 low-resource settings with the heaviest burden of disease. Papua New Guinea (Papua New
25 Guinea) has among the highest estimated burden of cervical cancer globally yet has no organized
26 national cervical screening programs. To better understand key informants’ perspectives of a
27 same day point-of-care HPV screen-and-treat program, we conducted key informant interviews
28 to capture their insights into the factors impacting the acceptability and sustainability of the
29 intervention.

30 **Methods:** We conducted a total of 26 semi-structured interviews with a purposive sample of 20
31 health care workers and six policymakers from Well Woman Clinics in Madang (Madang Province)
32 and Mt. Hagen (Western Highlands Province). Interviews were conducted in English, transcribed,
33 and analysed using thematic analysis, highlighting factors impacting the acceptability and
34 sustainability of the program from these key informants’ perspectives.

35 **Results:** The participants perceived the intervention as culturally fit and valuable. Health care
36 workers agreed that the technological elements of the intervention were easy to use and
37 provided the benefit of same day screen-and-treat, which helped to significantly reduce loss to
38 follow-up. Factors such as planning for key resources (i.e., financing, and human resources) and
39 political support were recognised as essential to ensure long-term sustainability by policymakers.
40 The intervention was valued as ‘scalable, portable and simple’, emphasizing that key political

41 support and a comprehensive national cervical cancer prevention strategy could help Papua New
42 Guinea make considerable headway toward cervical cancer elimination.

43 **Conclusion:** In light of the burden of cervical cancer in the country, all participants agreed that a
44 national cervical screening program, explicitly same day screen-and-treat services using self-
45 collection, addressed an immense unmet need and salient cultural and systemic barriers.

46

47

48 **Keywords:** HPV testing, screen-and-treat, acceptability, sustainability, qualitative research

49

50 **Contribution to literature:**

- 51 • This study is the first to explore factors impacting the acceptability and sustainability of a
- 52 point-of-care HPV self-collect same day screen-and-treat in a low resource setting
- 53 • The intervention was positively welcomed and assessed by all key informants
- 54 • Both health care workers and policymakers agree that this service is culturally congruent,
- 55 easy to use and implement, and is sustainable with consistent political and financial
- 56 support
- 57 • Key socio-cultural and systemic factors were identified as caveats that, if raised, could
- 58 potentially increase acceptability and sustainability of the program

59

60 Introduction

61 The emergence of molecular-based testing platforms and treatment technologies have reshaped
62 the early detection and treatment of cancers, most notably for cervical cancer, the fourth most
63 common cancer among women [1]. In 2020, the World Health Organization (WHO) outlined a
64 global strategy for the elimination of cervical cancer. Following HPV vaccination to prevent
65 infection, the two remaining pillars are designed to ensure no women and others already infected
66 with oncogenic HPV types die prematurely and needlessly from cervical cancer. In July 2021,
67 WHO updated its guidelines to recommend HPV screen-and-treat as the primary screening
68 modality [2]. As part of this impressive effort, and in recognition of the significant role it can play
69 in low- and middle-income countries (LMICs), WHO now recommends same day human
70 papillomavirus (HPV) screen-and-treat [3].

71

72 **Technological innovations for early detection and treatment of cervical changes**

73 With the use of innovative technological platforms, it is now possible to detect oncogenic HPV
74 types known to cause cervical cancer in cervical samples using a molecular platform using a
75 Polymerase Chain Reaction (PCR)-based assay [4, 5]. This technology has higher sensitivity and
76 specificity than conventional cytology methods for the detection of HPV, which requires women
77 and others at risk of cervical cancer to undergo cervical screening less frequently, and some PCR
78 tests are in formats that allow point-of-care by staff with minimal laboratory training [5-10]. The
79 point-of-care feature is particularly important in LMICs due to women facing challenges accessing
80 screening services associated with distance to health clinics, transportations costs (for repeated

81 visits), and household responsibilities [11-13]. Moreover, with effective training, the technology
82 allows for task-sharing among health care workers [14].

83 In settings where cervical screening uses traditional approaches such as the Pap test, the visual
84 inspection with acetic acid (VIA) and even clinician-collected swabs for HPV screening, women's
85 participation in screening programs has been declining over the years. One of the reasons noted
86 to be causing the decline is the embarrassment from the pelvic examination, among other
87 deterrents [15, 16]. Persistent socio-religious and cultural beliefs have impacted women's
88 experience with and perceptions of the pelvic examination [17]. Research shows that sexual
89 practices involving the female reproductive system, such as the Pap tests' pelvic exam, engenders
90 feelings of shame, embarrassment, and guilt, especially in countries with diverse cultural
91 backgrounds such as Papua New Guinea (Papua New Guinea) [18-20]. To address the shame and
92 stigma from the clinician-collected method (i.e., pelvic examination with the Pap test), scientists
93 developed the self-sampling (or self-collection) device that allows for women to collect their own
94 cervical samples. This novel collection method has shown to be comparable to clinical-collected
95 samples [9, 21, 22] and is widely preferred by women and others [23-26], citing its private nature,
96 ease of use, and increased access to the health system. Self-collection is increasingly being used
97 across the world in cervical screening programs, enabling women to self-collect in the clinic or
98 even in the privacy of their own home and post the sample back to the laboratory [27-29]. Self-
99 collection has the potential to significantly increase participation in screening programs in all
100 settings, most notably low-resource settings [25, 30-34].

101

102 **Cervical screening in Papua New Guinea**

103 In Papua New Guinea (Papua New Guinea), cervical cancer is the second most common cancer
104 [35]. In 2020 alone, Papua New Guinea recorded an age-standardized (ASR) cervical cancer
105 incidence rate and mortality rate of 29.2 cases per 100,000 and 19.1 cases per 100,000 women,
106 respectively [36]. Past screening services were reliant on Pap tests. This now outdated screening
107 method was reliant on highly trained staff, was resource intensive and without adequate
108 laboratory facilities could not be taken to scale. With cytology processing occurring offshore, in
109 Australia, the turnaround times meant women went without receiving their results. In 2009, a
110 pilot study was conducted in Papua New Guinea which used Visual Inspection with Acetic Acid
111 (VIA) and ablative cryotherapy [10] to provide same-day testing and treatment. However, the use
112 of VIA had low sensitivity and specificity which led to misdiagnoses and overtreatment and
113 required a pelvic/clinical examination. VIA also failed to overcome the barrier of an examination.

114

115 In 2018, a field prospective single-arm intervention study of same day screen/test-and-treat HPV-
116 based screening (HPV 'self-collect, test and treat' or HPV STAT) using self-collect, POC testing and
117 thermal ablation was implemented in two provinces in Papua New Guinea [5, 10, 37]. The testing
118 platform selected for this prospective single-arm intervention study was the Xpert (GeneXpert)
119 HPV test, which has been used in numerous LMICs in the diagnosis of infectious diseases such as
120 tuberculosis and other sexually transmitted infections [38]. The Xpert (GeneXpert) HPV test
121 allows for 60-90 minutes turnaround time for results, compared to a few hours for other similar
122 platforms. In performance studies, Xpert has shown to be an easy-to-use, scalable, effective, and

123 reliable diagnostic technology for point-of-care HPV testing [4, 5, 39, 40]. The clinical algorithm
124 used is detailed elsewhere [37].

125

126 **Key informants and cervical screening**

127 Health workers, along with program managers, are highly respected for their in-depth
128 understanding of the community, culture, and their role in the implementation of health
129 interventions [41, 42], while policymakers understand the health system and can offer their own
130 perspectives about systemic factors that could impact program implementation. Exploring the
131 perspective and experiences of key informants such as health care workers can offer valuable
132 insights into how socio-cultural, clinical, and systemic factors collide, to help catalyse investments
133 in cervical cancer prevention and control nationally [43].

134 Based on earlier social research in Papua New Guinea which sought to contextualise the socio-
135 cultural and biomedical understanding of cervical cancer and HPV vaccination for prevention
136 showed that women's understanding of what cervical cancer is, and what causes the disease was
137 ambiguous at best [44]. This same research showed that although knowledge of HPV as the
138 causative agent for cervical cancer was poorly understood, once the link was made, there was
139 widespread support from women, men, and key informants for a national roll out of HPV
140 vaccination; where there was discrepancy was between older and younger people about the
141 health communication messaging of the purpose of the vaccine [45, 46]. More recent qualitative
142 work has shown that women who have participated in Papua New Guinea's HPV STAT that self-
143 collection was highly acceptable. As part of this same HPV STAT program researchers have shown

144 that the PCR platform used for testing is efficacious and effective [5, 10, 47]. The next piece of
145 this growing body of knowledge about self-collected HPV screen-and-treat is the experiences and
146 perspectives of health workers and policymakers of a point-of-care early detection and treatment
147 cervical cancer program in the country.

148 As approaches to cervical screening rapidly evolve and are trialled and implemented in diverse
149 geographical as well as socio-political contexts, and global efforts are scaled up to eliminate
150 cervical cancer, it is imperative to continue to evaluate such programs from the point of view not
151 just of women but assess programs from the perspective of key informants. Through this study
152 and the data presented here in this paper we start to address this gap, examining HPV STAT from
153 a social research and implementation research perspective in an attempt to inform national
154 policies for cervical screening and treatment services in a high burden setting. This qualitative
155 study explores perspectives and experiences of key informants to understand the acceptability
156 and sustainability of a self-collected same day HPV screen-and-treat program in Papua New
157 Guinea, a setting where new approaches are urgently needed.

158

159 **Materials and Methods**

160 A qualitative study was undertaken as part of the larger multidisciplinary study exploring the
161 performance, cost-effectiveness, acceptability, and health systems requirement of a same day
162 approach for early detection and treatment of cervical precancerous lesions, using self-
163 collection. The field prospective single-arm intervention study was conducted at two Well
164 Women Clinics (WWC) in provincial hospitals in Papua New Guinea (Modilon General Hospital,

165 Madang Province and Mount Hagen General Hospital, Western Highlands Province). On arrival
166 at the clinics all attending women are given a health education talk (“Tok Save”) by health
167 workers. The health education talk covers risks and causes of cervical cancer (i.e., HPV as a
168 cancer-causing sexually transmitted infection), instructions for self-collection, and information
169 about the same screen-and-treat service, including how women who test positive for high-risk
170 HPV (hr-HPV) will be treated and triaged. All health care workers were trained to operate the
171 testing platform and interpret the results.

172 ***Study population and setting***

173 Semi-structured interviews were conducted with 26 key informants (20 health care workers and
174 6 policymakers) in Madang and Western Highlands Provinces. All interviews took place between
175 June 3rd and August 16th, 2019. We used purposive sampling to identify key health care workers
176 and policymakers with institutional knowledge and direct or indirect experience of implementing
177 HPV STAT [48]. The key informants were identified with the help of the PNGIMR team, and the
178 prospective single-arm intervention study’s principal investigator. During fieldwork, the pre-
179 identified key informants were called, emailed, or directly approached and asked to participate
180 in the interviews. This ensured a heterogeneous sample of participants with insightful, diverse,
181 and information rich narratives to address the research question at hand. Health care workers
182 included medical/nursing directors, senior hospital health care workers members, including
183 nurses, Obstetrics and Gynaecology ward staff and health extension officers (HEO). Policymakers
184 included senior-level directors or managers with over 15 years of experience in the national
185 health system. All policymakers involved were part of the Provincial Health Authority and were
186 key decisionmakers in health policy in their province.

187 ***Data collection and analysis***

188 The interviews ranged in length from 30-80 minutes (mean: 45 minutes). Two researchers (HC
189 and SN) conducted the interviews in English, and all were digitally audio-recorded. The first and
190 second authors conducted the interviews, with the second author being an experienced social
191 researcher from Papua New Guinea fluent in both English and Tok Pisin. With the help of the
192 Papua New Guinea Institute of Medical Research (PNGIMR), staff helped transcribe and translate
193 all the Tok Pisin interviews, while the first author transcribed all the interviews conducted in
194 English.

195 All participants were given an information and consent form in either English or Tok Pisin. The
196 form was explained to each of the participants to ensure all participants understood the purpose
197 of the interview, provided consent to participate, and signed the consent form before starting.
198 The interviews took place in conference rooms, office spaces, or at the clinic, ensuring the key
199 informants' privacy and security. All participants have been anonymized to protect their
200 identities. We used pseudonyms for all quotes in this paper to ensure our participants'
201 anonymity.

202 The first author used an interpretive approach to the data analysis. The process was iterative
203 throughout the analysis to capture experiences and perspectives impacting HPV STAT's
204 acceptability and sustainability. The first author conducted a line-by-line inductive thematic
205 analysis outlined by Braun and Clarke [49] to analyse the transcripts using the following six steps:
206 (1) transcription, (2) reading and re-reading to become familiar with the data, (3) coding, (3)
207 search for themes, (4) review the themes, (5) define and name the themes, and (6) finalize the

208 analysis. The lead author coded each transcript independently using QSR NVivo 12.5 [50]. The
209 first author focused on ‘micro to macro’ factors impacting acceptability and sustainability of the
210 program. Accordingly, she identified sub-themes that characterized their perspectives and
211 experiences impacting acceptability and sustainability from a personal, an interpersonal, and
212 from a health systems/policy point of view. These sub-themes were grouped into themes that
213 spoke to a social, clinical, and systemic views of the program. The author provided illustrative
214 quotes for each theme/sub-theme.

215 ***Ethics***

216 The team received ethical approval for this study and the larger prospective single-arm
217 intervention study from the Papua New Guinea Institute of Medical Research (PNGIMR)
218 Institutional Review Board (IRB), the Medical Research Advisory Committee (MRAC) of the Papua
219 New Guinea National Department of Health (NDoH), and the Human Research Ethics Committee
220 at UNSW Sydney.

221

222 **Results**

223 ***Participant demographics***

224 Of the 26 key informants interviewed, the majority were working and living in Madang (n=17,
225 65%). The key informants held several different types of positions in the provincial health service
226 including program directors (n=6, 23%), specialist Obstetricians/ Gynaecologists (n=5, 19%) and
227 nurses (n=5, 19%). Reflective of the health workforce more generally [51], most were female

228 (n=21, 81%). Of all the participants, most (n=17, 65%) had more than 15 years of experience in
 229 Papua New Guinea’s health system, with an average of 16.5 years.

230

Categories	Sub-categories	Madang		Mount Hagen		Combined	
		N=17	65%	N=9	35%	N=26	100%
Role	<i>CHW</i>	2	12	1	11	3	12
	<i>Director</i>	1	6	5	56	6	23
	<i>Health Manager</i>	0	0	1	11	1	4
	<i>HEO</i>	4	24	0	0	4	15
	<i>Midwife</i>	2	12	0	0	2	8
	<i>Nurse</i>	3	18	2	22	5	19
	<i>Physicians (Ob/Gyn)</i>	5	29	0	0	5	19
Sex	<i>Female</i>	16	94	5	56	21	81
	<i>Male</i>	1	6	4	44	5	19
Years in Papua New Guinea Health System	<i>Less than 5 years</i>	4	24	0	0	4	15
	<i>5-10 years</i>	1	6	0	0	1	4
	<i>10- 15 years</i>	4	24	0	0	4	15
	<i>More than 15 years</i>	8	47	9	100	17	65


231 Table 1. Participants demographics per site

232

233 Findings

234 Based on a thematic analysis there were three main overarching themes that were central to the
235 acceptability of the screening intervention: (1) embracing HPV STAT’s impact, values, and
236 opportunities: a social perspective; (2) engaging with point-of-care technology: a clinical
237 perspective; and (3) ensuring sustainability: a systems perspective. Themes 1 and 2 explore
238 factors influencing key informants’ acceptability of HPV STAT, and theme 3 explores the salient
239 factors required to sustain the program.

240



241

242 *Diagram 1. Thematic Analysis identifying factors impacting acceptability and sustainability*

243

244 **Embracing HPV STAT’s impact, values, opportunities: a social perspective**

245 The theme of ‘embracing HPV STAT’s impact, values, and opportunities’ details how the
246 participants perceived the intervention from a social perspective. In this section, we review key
247 stakeholder’s recognition that the program addresses key socio-cultural barriers and provides
248 opportunities for a wider national impact.

249 ***Perceived impact of HPV STAT***

250 A key discussion point in the interviews was cervical cancer’s insidious nature. The lack of
251 accessible and culturally congruent prevention services meant that women were dying early, and
252 most often experienced a physically and emotionally painful period of isolation in the later stages
253 of the disease due to the lack of treatment options. All key informants highlighted the imminent
254 need for effective and culturally sensitive preventive services against cervical precancer and
255 cancer. They perceived HPV STAT (‘the program’) as a social and clinical necessity to reduce the
256 burden of disease nationally. They emphasized that the program, as designed, addresses
257 numerous socio-cultural and systemic barriers that have hindered women from participating in
258 previous programs.

259 Another major cultural impact of the program is the self-collection of vaginal swabs, which was
260 identified as having a significant impact on women’s willingness to participate in screening.
261 Earlier strategies based on Pap test collection or VIA examination required all women to undergo
262 a pelvic examination which are poorly accepted due to embarrassment, discomfort, and cultural
263 contexts.

264 When we did the VIA [visual inspection with acetic acid], the mothers got scared like they
265 were ashamed because of our customs and all these things. They wouldn’t just come and

266 open themselves up for anybody to see them; they were a bit ashamed to come. But today
267 when we are saying that you will do your self-collection, a lot of mothers are coming up
268 to do that. They feel more comfortable in that way. (Marjorie, health care worker, 22
269 years of experience)

270 With the availability of self-collection, women have become even more active in their own care,
271 while at the same time becoming more self-aware of their bodies.

272 I see that [self-collection] has really encouraged women to come forward because they
273 are getting the specimen by themselves which they feel more comfortable and also, we
274 respect their privacy. They are empowered and they take ownership of their own health,
275 of their own well-being. I see that, that's very good, excellent idea because like I said
276 previously, they don't want to show themselves to other people. (Eloise, health care
277 worker, 20 years of experience)

278 In previous Pap test programs, several barriers contributed to most women being lost to follow-
279 up: the financial burden of transportation costs for frequent travel to the clinic (i.e., visit for the
280 screening, and return for the results and ongoing care), as well as delays in receiving their Pap
281 test results. The single visit (same day) point-of-care strategy allows for women to be tested and
282 treated on the same day, greatly reducing loss to follow-up, opportunity costs, and promoting
283 participation in screening. Senior health care workers and policymakers recognised that the
284 women-led program provides the directions, guidelines on how the country should move forward
285 in managing the disease.

286 Cervical cancer is becoming more common. This is an emerging disease that is killing a lot
287 of women in Papua New Guinea. So, when you think about something that could actually
288 save young girls and women from dying of a very high-risk disease... that is simple,
289 portable, scalable, women-led... we like it! (Jaden, policymaker, 20 years of experience)

290 ***Leveraging health education***

291 These one-hour sessions create an environment where women become more fully informed
292 about the service. This was an opportunity for health care workers to address individual concerns
293 and misunderstandings of/about the screen-and-treat procedure, such as seeking clarification
294 about the self-collection procedure, timing of results, and how to prevent cervical cancer in the
295 future.

296 A few caveats were raised by health care workers around the introduction of HPV as a causative
297 agent for cervical cancer. Despite attending the health education sessions, a few women
298 continued to believe that a positive HPV test meant they had cervical cancer. When discussing
299 this issue in their interviews, some health care workers stressed the importance of clarifying the
300 difference between testing positive for HPV and being diagnosed with cervical cancer to avoid
301 any misunderstandings and conflation of the two.

302 At first when we started doing it, those who tested positive were saying 'I have cancer',
303 and they think that we can't kill that cancer, but when they come back, we said, 'No, this
304 is not cancer.' The women who came after, we explain to them that if you have that virus,
305 it doesn't mean that you have cervical cancer. Just a virus is there, you don't necessarily
306 have cervical cancer. (Jaylene, health care worker, 13 years of experience)

307 Having received thermal ablation to treat the precancerous lesions, women who had tested
308 positive for HPV and undergone same day treatment were advised to abstain from vaginal
309 intercourse for six weeks. Abstinence is recommended to minimize the side effects of the thermal
310 ablation and promote cervical healing. According to key informants, for some of the women, this
311 post-care requirement created mistrust with their partners/husbands. To date men have not
312 attended the Well Women’s Clinic and have therefore not been privy to the health education
313 talks that explain this medical necessity for abstinence. The underlying reason for needing to
314 abstain –and to promote the healing process – is the issue that causes most of the tension in
315 relationships.

316 ***A naming dilemma: HPV testing or cervical cancer screening?***

317 Both health care workers and policymakers raised the importance of finding the correct way to
318 ‘name’ or ‘describe’ the service and viewed it as an opportunity to reduce the stigma around HPV
319 and cervical screening. In Papua New Guinea, discussions around topics such as sex, sexually
320 transmitted infections (STI), or the reproductive system can be highly stigmatized. Thus, naming
321 the testing service provided is of cultural significance and would profoundly impact acceptability
322 and uptake. The majority of health care workers and policymakers believed that the testing
323 (should be referred to as ‘cervical screening’ or ‘HPV testing’, albeit they acknowledged that
324 calling it HPV testing could be considered an important step in the right direction and would help
325 lessen any dissonance in communication pertaining to the service.

326 Using HPV testing is bold because people have to know that HPV causes cervical cancer.
327 It's like people are going for HIV testing. Now, we'll have to say that HPV testing is
328 available too. (Janelle, health care worker, 2 years of experience)

329 While the use of 'HPV testing' may be considered 'bold', some cautioned that it is important to
330 be sensitive and responsive to the stigma associated with HPV being an STI and to the diverse
331 cultural realities of each province in the country.

332 We need to be sensitive that what works in one province, may need tweaking for it to be
333 acceptable somewhere else. As long as we stick to the core things of it being something
334 that is going to avoid deaths from cervical cancer, it is a hard message to argue with. Now,
335 how you might talk about that STD part of HPV, to me, would be to dilute it, because the
336 other message [preventing deaths] is so incredibly powerful. (Mayna, policymaker, 23
337 years of experience)

338

339 **Engaging with point-of-care: a clinical perspective**

340 A key factor in evaluating the implementation of an intervention is assessing how it is viewed
341 from a clinical perspective. In this section, we review the clinical intervention, the clinical space,
342 and the clinical engagement.

343 ***Perceptions of HPV STAT's point-of-care technologies***

344 As part of the program, health care workers operated a diagnostic point-of-care technology to
345 test for the presence of hr-HPV DNA. Trust in the diagnostic technology is apparent from

346 discussions with both health care workers and policymakers. All health care workers were
347 confident in the use of the GeneXpert platform including its accuracy. Most felt that the use of
348 this closed molecular platform was more accurate than previous screening methods such as VIA.
349 Health care workers also acknowledged the quick result turnaround time of results using the
350 GeneXpert, noting that it allows for same day screen-and-treat. Most health care workers noted
351 the key aspects of time and speed, which help to address the high loss to follow-up rates
352 experienced with past Pap test programs.

353 All health care workers who have operated the HPV testing platform said that it was easy to use.
354 The testing platform interprets the results for the user, provides the exact HPV type(s) detected
355 in the sample, and also indicates when there is an issue with the sample (i.e., not enough sample
356 in the cartridge prompting for more sample collection). Similarly, policymakers agreed that the
357 machine is 'very effective and efficient'. Policymakers also commented on the machine's
358 mobility, alluding that it can be transported into hard-to-reach (rural) areas, where access to
359 cervical screening remains a challenge.

360 The addition of the precancerous treatment option on the same day was seen as an advantage.
361 All health care workers viewed the thermal ablation procedure as quick and effective.

362 ...with this [intervention], they come in and then they get the results on the same day and
363 it's possible they get treatment on the same day as well. That [same day screen-and-treat]
364 would be our greatest benefit to the women. (Jeffrey, health care worker, 16 years of
365 experience)

366 ***Teamwork and Training***

367 Staff at both WWC saw their role and the role of others in their team as equally important. The
368 effective teamwork stemmed from the clear delineation of roles as well as task sharing. The 'test
369 and treat' technologies are easy to use, allowing less skilled staff to operationalize Xpert, while
370 also leading health education sessions, and counselling the women throughout the clinical
371 pathway. The health care workers took particular pride in providing post-testing counselling,
372 seeing it as a significant role in the women's experience of HPV STAT.

373 The training model is one of coaching and supervision. Training consists of newly hired staff,
374 namely health extension officers and nurses, observing the most experienced health care
375 workers and being coached to perform all the steps. Task-shifting is an important advantage of
376 this intervention as all health care workers directly involved are health extension officers and/or
377 nurses, emphasizing the importance of their role in the intervention and in the Papua New
378 Guinean health system. The coaching and supervision scheme promotes a mentoring
379 environment. The staff felt supported by one another, creating a trusting work environment. The
380 staff felt empowered, not only through the use of the Xpert platforms but the role they each led
381 and being viewed as champions in their clinical and social environments. Policymakers suggested
382 that a similar coaching strategy should be used during scale-up to empower clinic staff, to
383 optimize on resources, and to create a supportive environment for all team members.

384 It seems to me that one of the biggest reasons this is going really well is the passion and
385 engagement [staff members] bring to our program. That's going to mean that we don't
386 just take our staff out of here, but we've got to grow someone like them in other places
387 and bring that person here for training, and then do the same thing again somewhere
388 else. (Mayna, policymaker, 23 years of experience)

389 ***Clinical Space***

390 According to all health care workers, the clinical space was well organized. Standard operating
391 procedures and other key documentation were available and well within reach of the staff. The
392 clinical algorithm posters were helpful to refer to when having conversations with the women
393 regarding the intervention. Nonetheless, the majority of health care workers suggested
394 improvements in a few areas. The size of the clinic was deemed too small. Due to the high uptake,
395 there was no adequate space for the women to sit and wait for their results. At times, the women
396 were too close to one another and could hear the other's results during their post-test
397 counselling. As much as the health care workers would attempt to ensure confidentiality during
398 those sessions, the limited space made it challenging.

399 These women are just sitting close to each other... we are sitting too close to interview
400 clients, and we need to keep their privacy. So, they're sitting close, and the others are
401 listening on the other side, it is not good. When we give results, others are still listening.
402 They'll go back and say this woman has that virus or something. We need to keep things
403 confidential. (Jaylene, health care worker, 13 years of experience)

404 As part of the program and to ensure women's privacy, a private space was dedicated to the self-
405 collection procedure and for women needing thermal ablation. Health care workers also
406 acknowledged the value of the dedicated private space for self-collection and the thermal
407 ablation procedure as part of the program. Similarly to the post-result counselling sessions,
408 health care workers emphasised the need for a larger clinical space in order to accommodate the
409 women and ensure privacy for these procedures. Moreover, the limited availability of a cervical

410 screening program in Papua New Guinea has left a void that HPV STAT is filling. Most health care
411 workers predicted an uptake due to increased awareness (i.e., word of mouth), high
412 acceptability, and immense need. It was suggested that, when considering the impact the service
413 could have on Papua New Guinea women long term, the service should have a space of their own
414 to respond to the demand.

415 If the hospitals all were willing to sustain the services, I think they should have a building
416 of its own so there's enough space, because it's a service in demand for women in the
417 province. (Jenny, health care worker, 17 years of experience)

418

419 **Ensuring Sustainability: a systems perspective**

420 A systems perspective focuses on how the intervention interacts with and impacts on the system
421 as a whole. The following will highlight key areas of improvement and/or consideration for scale
422 up and sustainability.

423 ***Mobilizing necessary resources***

424 Due to high acceptability of the program, health care workers underscored the need to hire for
425 more staff to sustain the service. Some of the health care workers suggested to train nurses,
426 health extension officers, and midwives currently working at the hospital, as a short-term
427 remedy.

428 The staff ratio to the number of women is overwhelming. For this particular clinic, even
429 with the two nurses that we have at the clinic, we are trying to strategize with the

430 numbers, but we are still overwhelmed with the numbers. The nurses to patient ratio is
431 still an extremely big gap. We can't match it. We might need additional help from other
432 departments as a start. (Jeffrey, health care worker, 16 years of experience)

433 ***Political support***

434 The introduction of HPV STAT prompted discussions about the need for a comprehensive national
435 cervical cancer prevention strategy including all preventive measures (i.e., HPV vaccination,
436 cervical screening, cervical cancer treatment services) to be made available to the public.
437 Policymakers stressed the importance of supporting the implementation of all three pillars of the
438 WHO cervical cancer elimination strategy. Yet, in order to see significant gains in cervical cancer
439 elimination nationally, it will require all pillars for sustained improved health outcomes in the
440 long term. Actualising this requires strong political support, notably political will, and direction.
441 This will ensure oversight of the infrastructure and logistics required to sustain the program, such
442 as the purchase of testing and treatment equipment, and key consumables (i.e., cartridges).

443 We will have to build that into the annual plan. There are some definite plans in place,
444 but that's for the hospital. We have to take it right across the province then. We need
445 good political will and directions from people higher up. They can get involved in the
446 infrastructure and logistics side of it and buy the machines and sustain the service with
447 getting its consumables like the cartridges and things like that. (Carl, senior policymaker,
448 22 years of experience)

449 Some respondents advocated for leadership at the provincial or national level to ensure more
450 coordinated effort to sustain HPV STAT.

451 The program needs a full-time person to coordinate and develop this. Bring everybody
452 together and run a full cervical cancer screening clinic for the province as a whole.
453 Everyone is busy with all the other responsibilities. So, to really scale it up across the
454 province, that would be really nice if we can do it... even nationally. With good political
455 direction and will, well-coordinated and a focal person, we can lead and sustain the
456 program. (Roger, senior health care worker, 14 years of experience)

457 ***Financing realities***

458 The cost and affordability of HPV STAT were raised by both health care workers and policymakers.
459 The current service is provided free of charge. While working women may be in a financial
460 position to pay in full or at least cost share as the program is taken to scale, it was recognized
461 that for the majority of women in Papua New Guinea this would not be possible. Yet, both health
462 care workers and policymakers recognized that it is essential to charge for the service if it needs
463 to be sustained. Senior-level health care workers and policymakers emphasized that an effective
464 financial strategy would allow the purchasing and maintenance of supplies and (extra) GeneXpert
465 machines essential to respond to the demand generated with the introduction of the service.

466 To really have an effective and sustainable program, women will have to be charged. I
467 would think that 60 Kina would be sufficient. 50 Kina is for cartridge. That extra 10 Kina
468 will be for treatment and many unseen costs that would be incurred. But that's from the
469 top of my head. I don't want it to be so hard for the families. But at the same time, I don't
470 want to be so cheap, and we struggle and close down the clinic. So, this could be a
471 balance. And if we have a reasonable balance like that, we ask the local MPs or the

472 government to support it, and we can just try it that way to start. (Peter, policymaker, 25
473 years of experience)

474

475 Discussion

476 On July 6th, 2021, the WHO launched its new guidelines for cervical cancer early detection and
477 treatment strongly recommending the screen (or test) and treat approach used and being
478 evaluated in Papua New Guinea since 2018. These findings on key informants' acceptability of
479 HPV STAT are thus, timely.

480 This is the first study to examine and report on the experiences and perspectives of health care
481 workers and policymakers of a point-of-care early detection and treatment cervical cancer
482 program in Papua New Guinea, and, as we understand, globally.

483 As part of our interest to explore factors impacting the implementation of a self-collect HPV
484 screen-and-treat program, we considered health care workers and policymakers' perceptions
485 and experiences of HPV STAT, focusing on perceptions of acceptability (i.e., the perception
486 among informants that a given treatment, service, practice, or innovation is agreeable, palatable
487 or satisfactory) and sustainability (i.e., the extent to which an intervention is maintained or
488 institutionalized in a given setting) [52]. The study has identified several important strengths of
489 the HPV STAT intervention that impacted its acceptability and sustainability.

490 Using the innovative HPV testing at point-of-care enabled a continuum of care that was not
491 possible in earlier cervical screening models, thus mitigating the unacceptably high loss to follow-
492 up seen in earlier programs. In this paper we have shown that key informants (and elsewhere the

493 women) trusted the PCR-based platform and its results and allowed for same day screen-and-
494 treat, which was highly valued by all informants, and for those operating the testing machine,
495 have found it was easy to use. Both health care workers and policymakers emphasized the value
496 of the intervention and its potential impact on women in the program but also the community
497 more widely. This is in line with the limited research that features the strengths of HPV testing
498 platforms [53]. The use of self-collection augmented the positive perspectives of the
499 intervention. Most health care workers perceived self-collection as private, easy to use and less
500 invasive than the pelvic examination. This is consistent with previous research highlighting key
501 features of the self-collection option [24, 26, 27].

502 These elements all contributed to the high acceptability of HPV STAT as a cervical screening
503 intervention in Papua New Guinea. As with all new interventions, we were able to identify a few
504 areas that should be considered during the scale-up of the program. Health care workers and
505 policymakers were both adamant that ensuring proper human resources for health (HRH)
506 coverage for the service is essential to sustain it. It was explained that lack of sufficient health
507 care workers might lead to drop-offs in uptake and threaten staff retention. Some suggested
508 strategies reinforcing task sharing with current staff at the hospital to address the imminent
509 need. Previous studies in similar low-resource settings have shed light on these concerns [54-56].
510 However, increasing staff and potential integration may lead to additional financial burden.
511 Sustaining the service, which include increasing staff, purchasing, and maintaining equipment
512 and supplies, requires a financing strategy that will allow to cover recurring costs. In addition,
513 integrating the service with other testing services (e.g., HIV testing and counselling) means
514 potentially stigmatizing the HPV testing program. A recently published study, the first of its kind,

515 detailed the costs and cost-effectiveness associated with HPV STAT. It was found that, HPV STAT,
516 more specifically the 5-year screening strategy, is more effective and cost-effective over time
517 compared to previous screening methods [57]. The study demonstrated that the same day
518 screen-and-treat modality is the best ‘value for money’, especially in high burden settings with
519 high loss to follow-up. The model predicts the annual cost of HPV STAT over the first five years at
520 approximately 3.3 million USD. Additional research is needed to explore key hidden costs and
521 potential solutions (e.g., costing, communication strategies) in Papua New Guinea and a myriad
522 of high burden settings, to strengthen the evidence base.

523 There is a paucity of qualitative research focusing on same day HPV screen and treat. Most of the
524 existing literature regarding same day ‘screen-and-treat’ pertains to the use of VIA as the
525 screening method of choice [58, 59]. Further research is necessary to qualitatively explore the
526 implementation of same-day screen-and-treat coupling point-of-care PCR-based technologies
527 and self-collection. This will allow to gage preferences from diverse perspectives, including
528 advantages and disadvantages of each option.

529

530 ***Limitations and strength of the study***

531 There are several limitations to this study. The use of a theory (e.g., CFIR, PRISM, RE-AIM) at the
532 onset of the qualitative study could have helped strengthened the analysis of the results to cover
533 difference aspects of acceptability and sustainability that were not highlighted in this manuscript.
534 Including national-level policymakers would have enriched the findings to better inform the
535 national strategy for cervical cancer prevention and control. Due to scheduling conflicts, one

536 interview was conducted with two policymakers, one more senior than the other. This could have
537 created some bias in the less senior respondent's responses during the interview process. This
538 study could have also included the women's viewpoints to supplement the perspectives
539 highlighted in the findings. The women's perspectives, however, will be published in a separate
540 article [60]. Because some of the health care workers' interviews occurred after the interviews
541 with policymakers, some of the health care workers' findings could not be followed up on or
542 discussed in more depth with policymakers about how the PNG health system could respond to
543 caveats that were raised. Yet, these findings provide a foundation for further studies to confirm
544 or add to the PNG experience.

545 The use of qualitative methods, however, presents a strength of the study. The use of interviews
546 helped to explore in depth a research area that has not yet been qualitatively investigated. This
547 study adds to the evidence base for an important public health measure, assessing two key
548 implementation outcome measures in a high burden setting. The sample includes both health
549 care workers and policymakers of different backgrounds and lengths of experience in the Papua
550 New Guinea health system, offering a variety of perspectives that helped enrich the results. Yet,
551 future research should include multiple other perspectives from other settings in the country for
552 a more comprehensive exploration of socio-cultural, clinical, and systemic factors impacting
553 acceptability and sustainability of HPV STAT. Moreover, additional qualitative research is needed
554 in different high burden settings to complement the results presented in this study and add to
555 the literature in support of the WHO screen-and-treat recommendation.

556

557 **Conclusion**

558 The quote ‘simple, portable, scalable, women-led... we like it!’ summarizes the health care
559 workers and policymakers’ perspectives of HPV STAT. This study highlights that innovative
560 technologies in cervical cancer early detection and treatment, such as HPV STAT, can be sustained
561 when key social, clinical, and systemic factors are considered during the design of the
562 intervention. In light of the burden of cervical cancer in Papua New Guinea, this qualitative study
563 demonstrated that a national culturally and financially appropriate cervical screening program,
564 explicitly self-collected HPV-based same day screen-and-treat services, fostered engagement of
565 health care workers and support from key policymakers. Whilst this study has raised a few
566 caveats, it has also shown that HPV STAT presents opportunities that could be the answer to
567 Papua New Guinea’s journey toward cervical cancer elimination.

568

569

570

571

572

573

574

575

576

577

578

579

580

581 **Declarations**

582 **Ethics approval and consent to participate**

583 This study was conducted as part of a National Health and Medical Research Council (NHMRC)
584 funded project grant (GNT1104938) 'Prospective cohort study to evaluate point-of care HPV-DNA
585 testing for the early detection and treatment of cervical pre-cancer in high-burden, low-resource
586 settings.' This study was approved by the PNG Institute of Medical Research Institutional Review
587 Board (IRB) (No. 1712), the Medical Research Advisory Committee (MRAC) of the PNG National
588 Department of Health (NDoH) (No. 17.36), and the Human Research Ethics Committee at UNSW
589 Sydney (No. HC17631). All participants signed an informed consent before participating in the
590 interviews.

591 **Consent for publication**

592 Not applicable.

593 ***Competing interests***

594 The authors declare that they have no competing interests.

595 ***Funding***

596 Funding was provided by the University of New South Wales scholarship Scientia scheme (to the
597 first author). This study is part of a doctoral research thesis.

598 **Authors' contributions**

599 HC designed, collected, and analysed the data, wrote, and revised the manuscript. HC conducted
600 and transcribed the interviews conducted in English. The Tok Pisin interviews were conducted,
601 translated, and transcribed by SN. SN assisted with participant recruitment. AV, RG and AKH
602 contributed to the design of the manuscript, the analysis, and the writing of the manuscript. All
603 authors read, critically reviewed, and approved the final manuscript.

604 **Availability of Data and Materials**

605 The data used and analyzed for this study were not made publicly available to protect
606 participants' privacy but are available from the corresponding author on reasonable request.

607 ***Acknowledgements***

608 The authors would like to thank all the participants, the PNG IMR team, Modilon Hospital Well
609 Women's Clinic and Mount Hagen General Hospital Well Women's Clinic staff members for their
610 instrumental support during the first author's fieldwork. The authors would also wish to
611 acknowledge the senior level staff at both Modilon General Hospital and Mount Hagen General
612 Hospital for their hospitality, time, and support of this study.

613 ***Authors' affiliation:***

614 **Kirby Institute for Infection and Immunity in Society, UNSW Sydney, Wallace Wurth Building,**
615 **UNSW Sydney, NSW 2052, Australia**

616 Hawa Camara, Steven G Badman, Rebecca Guy, Andrew J. Vallely, Angela Kelly-Hanku
617 **Papua New Guinea Institute of Medical Research, Homate Street, PO Box 60, Goroka, Eastern**
618 **Highlands Province**
619 Somu Nosi, Gloria Munnall
620 **Modilon General Hospital, Department of Obstetrics & Gynaecology, PO Box 1200, Madang,**
621 **Papua New Guinea**
622 John Bolgna
623 **Mt Hagen Provincial Hospital, PO Box 36, Mt Hagen, WHP 281, Papua New Guinea**
624 Joseph Kuk
625 **School of Medicine and Health Sciences, University of Papua New Guinea, PO Box 5623 Boroko,**
626 **NCD, Papua New Guinea**
627 Glen Mola
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643

644 **References**

- 645 1. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J et al. Estimates of
646 incidence and mortality of cervical cancer in 2018: A worldwide analysis. *Lancet Glob*
647 *Health*, 2020. **8**(2):e191-e203.
- 648 2. World Health Organization. WHO guideline for screening and treatment of cervical
649 precancer lesions for cervical cancer prevention, second edition. 2021. Geneva: World
650 Health Organization.
- 651 3. World Health Organization. Global strategy to accelerate the elimination of cervical
652 cancer as a public health problem. 2020. Geneva: World Health Organization.
- 653 4. Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, et al. Performance of
654 the Xpert HPV assay in women attending for cervical screening. *Papillomavirus Res*, 2015.
655 **1**:32-7.
- 656 5. Toliman P, Badman SG, Gabuzzi J, Silim S, Forereme L, Kumbia A, et al. Field evaluation of
657 Xpert HPV point-of-care test for detection of human papillomavirus infection by use of
658 self-collected vaginal and clinician-collected cervical specimens. *J Clin Microbiol*, 2016.
659 **54**(7):1734-7.
- 660 6. Mohammed SI, Ren W, Flowers L, Rajwa B, Chibwasha CJ, Parham GP, et al. Point-of-care
661 test for cervical cancer in LMICs. *Oncotarget*, 2016. **7**(14):18787-97.
- 662 7. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure requirements
663 for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
664 *Vaccine*, 2013. **31**(Suppl 5):F47-52.
- 665 8. Denny LA, Sankaranarayanan R, De Vuyst H, Kim JJ, Adefuye PO, Alemany L, et al.
666 Recommendations for cervical cancer prevention in sub-saharan Africa. *Vaccine*, 2013.
667 **31**(Suppl 5):F73-4.
- 668 9. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, et al. Diagnostic
669 accuracy of self collected vaginal specimens for human papillomavirus compared to
670 clinician collected human papillomavirus specimens: a meta-analysis. *Sex Transm Infect*,
671 2005. **81**(3):207-12.
- 672 10. Toliman PJ, Kaldor JM, Badman SG, Gabuzzi J, Silim S, Kumbia A, et al. Performance of
673 clinical screening algorithms comprising point-of-care HPV-DNA testing using self-
674 collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the
675 detection of underlying high-grade squamous intraepithelial lesions in Papua New
676 Guinea. *Papillomavirus Res*, 2018. **6**:70-6.
- 677 11. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic point-
678 of-care tests in resource-limited settings. *Lancet Infect Dis*, 2014. **14**(3):239-49.
- 679 12. Garcia PJ, You P, Fridley G, Mabey D, Peeling R. Point-of-care diagnostic tests for low-
680 resource settings. *Lancet Glob Health*, 2015. **3**(5):e257-e258.
- 681 13. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing
682 countries at a crossroad: Emerging technologies and policy choices. *World J Clin Oncol*,
683 2015. **6**(6):281-90.
- 684 14. Umuago IJ, Obiebi IP, Eze GU, Zini M, Okoacha I. Bridging the gap in health systems
685 through task-sharing: a model of PHC workers' competency for cervical screening. *J*
686 *Cancer Res Pract*, 2018. **5**(4):141-8.

- 687 15. Barbee L, Kobetz E, Menard J, Cook N, Blanco J, Barton B, et al. Assessing the acceptability
688 of self-sampling for HPV among Haitian immigrant women: CBPR in action. *Cancer Cause*
689 *Control*, 2010. **21**(3):421-31.
- 690 16. Menard JM. The social context of cervical cancer knowledge and prevention among
691 Haitian immigrant women. PhD thesis. 2008, University of South Florida. p. 355.
- 692 17. Driscoll SD. Barriers and facilitators to cervical cancer screening in high incidence
693 populations: A synthesis of qualitative evidence. *Women Health*, 2016. **56**(4):448-67.
- 694 18. Vallely A, Fitzgerald L, Fiya V, Aeno H, Kelly A, Sauk J, et al. Intravaginal practices and
695 microbicide acceptability in Papua New Guinea: Implications for HIV prevention in a
696 moderate-prevalence setting. *BMC Res Notes*, 2012. **5**:613.
- 697 19. Teng FF, Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JK, Steinberg M, et al.
698 Understanding the role of embarrassment in gynaecological screening: A qualitative study
699 from the ASPIRE cervical cancer screening project in Uganda. *BMJ Open*, 2014.
700 **4**(4):e004783.
- 701 20. Linde DS, Rasch V, Mwaiselage JD, Gammeltoft TM. Competing needs: A qualitative study
702 of cervical cancer screening attendance among HPV-positive women in Tanzania. *BMJ*
703 *Open*, 2019. **9**(2):e024011.
- 704 21. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected
705 samples comparable to physician-collected cervical specimens for human papillomavirus
706 DNA testing? A systematic review and meta-analysis. *Gynecol Oncol*, 2007. **105**(2):530-5.
- 707 22. Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, et al. Human
708 papillomavirus testing by self-sampling: Assessment of accuracy in an unsupervised
709 clinical setting. *J Med Screening*, 2007. **14**:34-42.
- 710 23. Arrossi S, Ramos S, Straw C, Thouyaret L, Orellana L. HPV testing: A mixed-method
711 approach to understand why women prefer self-collection in a middle-income country.
712 *BMC Public Health*, 2016. **16**:832.
- 713 24. Bansil P, Wittet S, Lim JL, Winkler JL, Paul P, Jeronimo J. Acceptability of self-collection
714 sampling for HPV-DNA testing in low-resource settings: A mixed methods approach. *BMC*
715 *Public Health*, 2014. **14**:596.
- 716 25. Creagh NS, Zammit C, Brotherton JM, Saville M, McDermott T, Nightingale C, et al. Self-
717 collection cervical screening in the renewed National Cervical Screening Program: a
718 qualitative study. *Med J Aust*, 2021. **215**(8):354-8.
- 719 26. Camara H, Zhang Y, Lafferty L, Vallely AJ, Guy R, Kelly-Hanku A. Self-collection for HPV-
720 based cervical screening: A qualitative evidence meta-synthesis. *BMC Public Health*, 2021.
721 **21**(1):1503.
- 722 27. Brandt T, Wubneh SB, Handebo S, Debalkie G, Ayanaw Y, Alemu K, et al. Genital self-
723 sampling for HPV-based cervical cancer screening: A qualitative study of preferences and
724 barriers in rural Ethiopia. *BMC Public Health*, 2019. **19**(1):1026.
- 725 28. Katz ML, Zimmermann BJ, Moore D, Paskett ED, Reiter PL. Perspectives from health-care
726 providers and women about completing human papillomavirus (HPV) self-testing at
727 home. *Women Health*, 2017. **57**(10):1161-77.
- 728 29. Esber A, Norris A, Jumbe E, Kandodo J, Nampondeni P, Reese PC, et al. Feasibility, validity
729 and acceptability of self-collected samples for human papillomavirus (HPV) testing in rural
730 Malawi. *Malawi Med J*, 2018. **30**(2):61-6.

- 731 30. Franco EL. Self-sampling for cervical cancer screening: Empowering women to lead a
732 paradigm change in cancer control. *Curr Oncol*, 2018. **25**(1):e1-e3.
- 733 31. Gupta S, Palmer C, Bik EM, Cardenas JP, Nunez H, Kraal L, et al. Self-sampling for human
734 papillomavirus testing: Increased cervical cancer screening participation and
735 incorporation in international screening programs. *Front Public Health*, 2018. **6**:77.
- 736 32. Pedersen HN, Smith LW, Racey CS, Cook D, Krajden M, van Niekerk D, et al.
737 Implementation considerations using HPV self-collection to reach women under-
738 screened for cervical cancer in high-income settings. *Curr Oncol*, 2018. **25**(1):e4-e7.
- 739 33. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in
740 cervical cancer screening: A systematic review and meta-analysis. *Can J Public Health*,
741 2013. **104**(2):159-66.
- 742 34. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al. Human papillomavirus
743 and related diseases in Papua New Guinea. 2019. Lyon, France. ICO/IARC Information
744 Centre on HPV and Cancer (HPV Information Centre).
- 745 35. International Agency for Research on Cancer (IARC). The Global Cancer Observatory
746 (Globocan): Papua New Guinea. 2020. Geneva: World Health Organization.
- 747 36. Vallely A, Toliman P. Health service delivery models for scaling use of point-of-care HPV
748 'test and treat' strategies in high-burden, low-income settings. *J Virus Eradication*, 2019.
749 **5**(Suppl 1):1-3.
- 750 37. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al. The impact and
751 cost of scaling up GeneXpert MTB/RIF in South Africa. *PLoS One*, 2012. **7**(5):e36966.
- 752 38. Castle PE, Smith KM, Davis TE, Schmeler KM, Ferris DG, Savage AH, et al. Reliability of the
753 Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral
754 population. *Am J Clin Pathol*, 2015. **143**(1):126-33.
- 755 39. Mbulawa ZZA, Wilkin TJ, Goeieman B, Swarts A, Williams S, Levin S, et al. Xpert human
756 papillomavirus test is a promising cervical cancer screening test for HIV-seropositive
757 women. *Papillomavirus Res*, 2016. **2**:56-60.
- 758 40. Tynan A, Vallely A, Kelly A, Kupul M, Neo J, Naketrumb R, et al. Sociocultural and individual
759 determinants for motivation of sexual and reproductive health workers in Papua New
760 Guinea and their implications for male circumcision as an HIV prevention strategy. *Hum
761 Resour Health*, 2013. **11**:7.
- 762 41. Field E, Dove G, Witi N, Abo D, Samiak L, Vallely L, et al. Perceptions of the Village Health
763 Volunteer Program implementation in remote Papua New Guinea: lessons for policy. *PNG
764 Med J*, 2019. **62**(1-2):19-32.
- 765 42. Belaid L, Ridde V. Contextual factors as a key to understanding the heterogeneity of
766 effects of a maternal health policy in Burkina Faso? *Health Policy Plan*, 2015. **30**(3):309-
767 21.
- 768 43. Kelly-Hanku A, Ase S, Fiya V, Toliman P, Aeno H, Mola GM, et al. Ambiguous bodies,
769 uncertain diseases: Knowledge of cervical cancer in Papua New Guinea. *Ethn Health*,
770 2018. **23**(6):659-81.
- 771 44. Kelly-Hanku A, Newland J, Aggleton P, Ase S, Aeno H, Fiya V, et al. HPV vaccination in
772 Papua New Guinea to prevent cervical cancer in women: Gender, sexual morality,
773 outsiders and the de-feminization of the HPV vaccine. *Papillomavirus Res*, 2019.
774 **8**:100171.

- 775 45. Kelly-Hanku A, Newland J, Aggleton P, Ase S, Fiya V, Aeno H, et al. Health communication
776 messaging about HPV vaccine in Papua New Guinea. *Health Education J*, 2019. **78**(8):946-
777 57.
- 778 46. Vallely A, Mola GDL, Kaldor JM. Achieving control of cervical cancer in Papua New Guinea:
779 What are the research and program priorities? *PNG Med J*, 2011. **54**(3-4):83-90.
- 780 47. Braun V, Clarke V. *Successful qualitative research: A practical guide for beginners*. 2013.
781 London: SAGE Publications Ltd. 382.
- 782 48. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*, 2006. **3**:77-
783 101.
- 784 49. QSR. NVivo qualitative data analysis software. 2018.
- 785 50. World Health Organization. *Global strategy on human resources for health: Workforce*
786 *2030*. 2016. Geneva: World Health Organization.
- 787 51. Peters DH, Adam T, Alonge O, Agyepong IA, Tran N, Peters DH. Implementation research:
788 What it is and how to do it. *Br J Sports Med*, 2014. **48**:731-6.
- 789 52. Woo YL, Gravitt P, Khor SK, Ng CW, Saville M. Accelerating action on cervical screening in
790 lower- and middle-income countries (LMICs) post COVID-19 era. *Prev Med*, 2021.
791 **144**:106294.
- 792 53. Camara H, Zhang Y, Lafferty L, Vallely AJ, Guy R, Kelly-Hanku A. Self-collection for HPV-
793 based cervical screening: A qualitative evidence meta-synthesis. *BMC Public Health*, 2021.
794 **21**(1).
- 795 54. Holme F, Kapambwe S, Nessa A, Basu P, Murillo R, Jeronimo J. Scaling up proven
796 innovative cervical cancer screening strategies: Challenges and opportunities in
797 implementation at the population level in low- and lower-middle-income countries. *Int J*
798 *Gynaecol Obstet*, 2017. **138**(Suppl 1):63-8.
- 799 55. Rosser JI, Hamisi S, Njoroge B, Huchko MJ. Barriers to cervical cancer screening in rural
800 Kenya: Perspectives from a provider survey. *J Community Health*, 2015. **40**(4):756-61.
- 801 56. White HL, Meglioli A, Chowdhury R, Nuccio O. Integrating cervical cancer screening and
802 preventive treatment with family planning and HIV-related services. *Int J Gynaecol*
803 *Obstet*, 2017. **138**(Suppl 1):41-46.
- 804 57. Nguyen DTN, Simms KT, Keane A, Mola G, Bolnga JW, Kuk J, et al. Towards the elimination
805 of cervical cancer in low-income and lower-middle-income countries: Modelled
806 evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected
807 screening and treatment in Papua New Guinea. *BMJ Glob Health*, 2022. **7**(3).
- 808 58. Moucheraud C, Kawale P, Kafwafwa S, Bastani R, Hoffman RM. Health care workers'
809 experiences with implementation of "screen and treat" for cervical cancer prevention in
810 Malawi: A qualitative study. *Implement Sci Commun*, 2020. **1**(1):112.
- 811 59. Paul P, Winkler JL, Bartolini RM, Penny ME, Huong TT, Nga LT, et al. Screen-and-treat
812 approach to cervical cancer prevention using visual inspection with acetic acid and
813 cryotherapy: Experiences, perceptions, and beliefs from demonstration projects in Peru,
814 Uganda, and Vietnam. *Oncologist*, 2013. **18**(12):1278-84.
- 815 60. Camara H, Nosi S, Gabuzzi J, Munnall G, Badman S, Bolnga J, Kuk J, Mola G, Guy R, Vallely
816 A, Kelly-Hanku A. Women's acceptability of a self-collect HPV same-day screen-and-treat
817 program in a high burden setting in the Pacific. *BMC Health Serv Res* 2022. **22**(1514).
818